Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Improved Tolerability Of Neratinib In Patients With Her2-Positive Early-Stage Breast Cancer: The Control Trial, C H Barcenas, R Bose, Et Al.
Improved Tolerability Of Neratinib In Patients With Her2-Positive Early-Stage Breast Cancer: The Control Trial, C H Barcenas, R Bose, Et Al.
2020-Current year OA Pubs
BACKGROUND: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which no antidiarrheal prophylaxis was mandated, grade 3 diarrhea was observed in 40% of patients and 17% discontinued due to diarrhea. The international, open-label, sequential-cohort, phase II CONTROL study is investigating several strategies to improve tolerability.
PATIENTS AND METHODS: Patients who completed trastuzumab-based adjuvant therapy received neratinib 240 mg/day for 1 year plus loperamide prophylaxis (days 1-28 or 1-56). Sequential cohorts evaluated additional budesonide or colestipol prophylaxis (days 1-28) and …
Tfeb Is A Master Regulator Of Tumor-Associated Macrophages In Breast Cancer, Yong Li, Johnie Hodge, Qing Liu, Junfeng Wang, Yuzhen Wang, Trent D Evans, Diego Altomare, Yongzhong Yao, E. Angela Murphy, Babak Razani, Daping Fan
Tfeb Is A Master Regulator Of Tumor-Associated Macrophages In Breast Cancer, Yong Li, Johnie Hodge, Qing Liu, Junfeng Wang, Yuzhen Wang, Trent D Evans, Diego Altomare, Yongzhong Yao, E. Angela Murphy, Babak Razani, Daping Fan
2020-Current year OA Pubs
BACKGROUND: Tumor-associated macrophages (TAMs) play key roles in the development of many malignant solid tumors including breast cancer. They are educated in the tumor microenvironment (TME) to promote tumor growth, metastasis, and therapy resistance. However, the phenotype of TAMs is elusive and how to regulate them for therapeutic purpose remains unclear; therefore, TAM-targeting therapies have not yet achieved clinical success. The purposes of this study were to examine the role of transcription factor EB (TFEB) in regulating TAM gene expression and function and to determine if TFEB activation can halt breast tumor development.
METHODS: Microarrays were used to analyze the …
Breast Cancer Risk, Worry, And Anxiety: Effect On Patient Perceptions Of False-Positive Screening Results, Janie M. Lee, Kathryn P. Lowry, Jessica E. Cott Chubiz, J. Shannon Swan, Tina Motazedi, Elkan F. Halpern, Anna N. A. Tosteson, G. Scott Gazelle, Karen Donelan
Breast Cancer Risk, Worry, And Anxiety: Effect On Patient Perceptions Of False-Positive Screening Results, Janie M. Lee, Kathryn P. Lowry, Jessica E. Cott Chubiz, J. Shannon Swan, Tina Motazedi, Elkan F. Halpern, Anna N. A. Tosteson, G. Scott Gazelle, Karen Donelan
2020-Current year OA Pubs
OBJECTIVE: The impact of mammography screening recall on quality-of-life (QOL) has been studied in women at average risk for breast cancer, but it is unknown whether these effects differ by breast cancer risk level. We used a vignette-based survey to evaluate how women across the spectrum of breast cancer risk perceive the experience of screening recall.
METHODS: Women participating in mammography or breast MRI screening were recruited to complete a vignette-based survey. Using a numerical rating scale (0-100), women rated QOL for hypothetical scenarios of screening recall, both before and after benign results were known. Lifetime breast cancer risk was …
Associations Between Breast Cancer Subtype And Neighborhood Socioeconomic And Racial Composition Among Black And White Women, Erin Linnenbringer, Arline T Geronimus, Kia L Davis, John Bound, Libby Ellis, Scarlett L Gomez
Associations Between Breast Cancer Subtype And Neighborhood Socioeconomic And Racial Composition Among Black And White Women, Erin Linnenbringer, Arline T Geronimus, Kia L Davis, John Bound, Libby Ellis, Scarlett L Gomez
2020-Current year OA Pubs
PURPOSE: Studies of Black-White differences in breast cancer subtype often emphasize potential ancestry-associated genetic or lifestyle risk factors without fully considering how the social or economic implications of race in the U.S. may influence risk. We assess whether neighborhood racial composition and/or socioeconomic status are associated with odds of triple-negative breast cancer (TNBC) diagnosis relative to the less-aggressive hormone receptor-positive/HER2-negative subtype (HR+ /HER-), and whether the observed relationships vary across women's race and age groups.
METHODS: We use multilevel generalized estimating equation models to evaluate odds of TNBC vs. HR+ /HER2- subtypes in a population-based cohort of 7291 Black and …
Targeted Therapy For Advanced Salivary Gland Carcinoma Based On Molecular Profiling: Results From Mypathway, A Phase Iia Multiple Basket Study, R Kurzrock, D W Bowles, H Kang, F Meric-Bernstam, J Hainsworth, D R Spigel, R Bose, H Burris, C J Sweeney, M S Beattie, S Blotner, K Schulze, V Cuchelkar, C Swanton
Targeted Therapy For Advanced Salivary Gland Carcinoma Based On Molecular Profiling: Results From Mypathway, A Phase Iia Multiple Basket Study, R Kurzrock, D W Bowles, H Kang, F Meric-Bernstam, J Hainsworth, D R Spigel, R Bose, H Burris, C J Sweeney, M S Beattie, S Blotner, K Schulze, V Cuchelkar, C Swanton
2020-Current year OA Pubs
BACKGROUND: Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics.
PATIENTS AND METHODS: MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate …